Micro cap Novavax (NVAX +36%) is totally ignoring the broad market’s sour mood on triple normal volume. Shares have rallied over 40% this week after it announced positive one-year data on RSV vaccine ResVax on Monday.
On the working capital front, at the end of June it had $72M in cash and equivalents while operations consumed ($80.6M) in H1.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.